Skip to main content

List of patents
CODE DESCRIPTION PRIORITY LICENSE
98002 IFNa5 Interferon alfa 5 use as antiviral for hepatitis C treatment Sol. ES9801003; 13/05/1998 DIGNA BIOTECH
98003 iTGFb1 Peptide inhibitors of TGF beta 1 Sol. ES9802465; 24/11/1998 DIGNA BIOTECH
01005 snRNPU1mod Reversible inhibition of gene expression by modified ribonucleoprotein U1 Sol. ES200100765; 30/03/2001 Joint owner with University of Rutgers (USA)
01008 CT-1 Use of Cardiotrophine (CT-1) for the treatment of human liver diseases Sol. ES200102120; 21/09/2001 DIGNA BIOTECH
02007 iTGFb1 II Peptides Inhibitors of TGF-beta 1 (II) Sol. ES200302020; 22/08/2003 DIGNA BIOTECH
03001 EPCR New method for thrombosis risk evaluation by measuring EPCR auto-antibody in plasma Sol. ES200400269; 06/02/2004 DIGNA BIOTECH
03004 AdSFV Vec Hybrid virus (Adenovirus-alfa/ Semliky Forest) to administer and express therapeutics genes in tumour cells Sol. ES200401219; 20/05/2004 DIGNA BIOTECH
04005 AR Use of anfirreguline as acute liver protectant agent Sol. ES200401776; 20/07/2004 DIGNA BIOTECH
04011 ApoA1 HCC Oxidised Apo A1 as early markers of Hepatocellular carcinoma Sol. ES200402989; 16/12/2004 DIGNA BIOTECH
05003 MAPC Vascular/Lymphatic Endothelial Cells derived from mature adult stem cell Sol.US 60/652,015; 10/02/200 Joint owner with University of Minnesota (USA)
04007 nsEPCR New soluble ePCR protein as trombotic marker and potential therapeutic agent Sol. ES200500623; 17/03/2005 DIGNA BIOTECH
04016 MTA Autoin 5'-metiltioadenosina (MTA) in the prevention and treatment of autoimmune diseases PCT/ES 2005/000139; 17/03/2005 DIGNA BIOTECH
05004 EWS-FLI1 Animal model of human Ewing sarcoma PCT/ES 2005/000234; 29/04/2005  
05008 IFNa.CT1 Use of cardiotropline-1 (CT-1) and alfa interferon (IFNa) for combined treatment in viral diseases Sol. ES200501468; 16/06/2005 DIGNA BIOTECH
05012 URIFIB Fibrosis markers in urine Sol. ES200501611; 01/07/2005 DIGNA BIOTECH
04018 EDA Vac Use of EDA as immune-modulator agent Sol. ES200501412; 13/06/2005 DIGNA BIOTECH
05013 HCC.Prof A selection of hepatocellular carcinoma markers Sol. ES200502369; 29/09/2005 DIGNA BIOTECH
05009 HCV poliIC.aCD40 Immune-stimulatory combination for hepatitis C prevention Sol. ES200502446; 07/10/2005
Sol. ES20060156; 09/06/2006
DIGNA BIOTECH
05030 iTGFb1 INMUN Use of peptides inhibitor of TGF-beta1 as a immune response modulator PCT/ES 2005/002446; 24/10/2005 DIGNA BIOTECH
05019 CRAds New recombinant adenovirus with conditionated replication Sol. ES200503047; 12/12/2005 DIGNA BIOTECH
05029 DTh.panDR New synthetic peptides as T helper (DTh) determinant for universal DR Sol. ES200503169; 23/12/2005  
06010 BrC.Predictor 11q deletion as a molecular genetic marker in breast cancer Sol. US11/382,99; 12/05/2006 Joint owner with University of California (USA)
05018 Línea NSCLC Experimental model for bond metastasis from lung cancer Sol. ES200602349; 15/09/200  
06016 iIL10 IL-10 inhibitors peptides (iIL-10) Sol. ES200700806; 27/03/2007  
06022 Prot.Prod Viral vector as producer for stable cell line generation Sol. ES200700882; 03/04/2007  
06024 iFoxp3 Escurfine inhibitors peptides(i Fox p3) Sol. ES200703052; 19/11/2007 DIGNA BIOTECH
06031 MMP10.coag Metalloproteinase 10 as adjuvant for trombolitic treatment (MMP10) Sol. ES200700501; 26/02/2007 DIGNA BIOTECH
07014 aMMP10.Blood Metalloproteinase 10 Inhibitors as anti-fibrinolitic treatment (iMMP10) Sol. ES200701786; 26/06/2007 DIGNA BIOTECH
07016 TGFb1-MMPs Metalloproteinase in combination with iTGF beta for metastasis treatment (MMPs+iTGFbeta-1) Sol. ES200702309; 20/08/2007 DIGNA BIOTECH
05033 PPARa CPH Inhibitors of PPAR alfa truncated for heart failure prevention in hypertension (iPPAR truncated) Sol. ES200702625; 05/10/2007 DIGNA BIOTECH
07005 IFN.CD137 Association of alfa interferon to 4-1BB agonist antibodies for antitumoral treatment (alfa INF+4-1BB agonist) Sol. ES200702961; 07/11/2007  
07027 IL12.iTGFb1 iTGF beta 1 as adjuvant for the antitumoral effect of IL12 induced expression (IL12+iTGF beta1) Sol. ES200800417; 15/02/2008  
07024 U1.RNAi Synergy of silencing post-transcriptional genes combining mRNAi and  snRNP (mRNAi + sn RNP U1 Sol. ES200800222; 29/01/2008  
06027 PCP.PCPE Methods for the treatment of cardiac disease associated to myocardial fibrosis PCT/EP 2008/051347; 04/02/2008  

© Proyecto de Biomedicina CIMA S.L.

Etxesakan 28 - Oficina 5 (Edificio AZYSA) · 31180 Zizur Mayor · Navarra · Spain · T +34 948 287 561 · F +34 948 180 500 · info@proyectobiocima.com